Press Releases Ocular Therapeutix, Inc.

Stocks

OCUL

US67576A1007

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 12:21:16 2026-06-11 pm EDT			5-day change	1st Jan Change
8.630 ^USD	-1.26%		+0.40%	-27.22%

May. 14	EyePoint's late-stage eye drug trials to continue after safety panel review	RE
May. 12	Ocular Therapeutix, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03:40 PM

Press Releases

Jun. 08	Ocular Therapeutix Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
Jun. 05	Ocular Therapeutix to Participate in Clinical Trials at the Summit 2026	AQ
Jun. 05	Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
Jun. 04	Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026	AQ
Jun. 02	Ocular Therapeutix™ to Host Investor Day on June 17, 2026	AQ
May. 08	Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
May. 05	Ocular Therapeutix: Q1 Earnings Snapshot	AQ
May. 05	Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights	AQ
Apr. 30	Ocular Therapeutix Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI in Wet AMD	AQ
Apr. 29	Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD	AQ
Apr. 28	Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026	AQ
Apr. 27	Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences	AQ
Apr. 22	Ocular Therapeutix™ to Host Investor Day on June 17, 2026	AQ
Apr. 15	Ocular Therapeutix Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
Apr. 14	Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
Apr. 13	Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD	AQ
Apr. 01	Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April	AQ
Mar. 09	Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
Feb. 24	Ocular Therapeutix™ to Participate in March Investor Conferences	AQ
Feb. 23	Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations	AQ
Feb. 19	Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses	NE
Feb. 18	Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses	AQ
Feb. 16	Ocular Therapeutix to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026	AQ
Feb. 13	Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026	AQ
Feb. 06	Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ